CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • March 1st, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 5th day of January, 2021 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Renee Lentini (the “Executive”).
ADDENDUM A TO MICHAEL J. VASCONCELLES OFFER LETTER CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • March 1st, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 29th day of December, 2022 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Michael Vasconcelles (the “Executive”).
IMMUNOGEN, INC. RESTRICTED STOCK UNIT TERMS AND CONDITIONSRestricted Stock Unit Agreement • March 1st, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This Restricted Stock Unit Agreement is entered into and made effective as of the grant date referenced in the Grant Detail (the “Grant Date”) and is between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and the employee of the Company (the “Participant”) referenced in the Grant Detail. Certain capitalized terms, to the extent not defined where they first appear in this Restricted Stock Unit Agreement, are defined in the Company’s Inducement Equity Incentive Plan (as amended from time to time, the “Plan”).
RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE IMMUNOGEN, INC. AMENDED AND RESTATED 2018 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLANRestricted Stock Unit Agreement • March 1st, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This agreement (this “Agreement”) evidences an award (the “Award”) of restricted stock units granted by ImmunoGen, Inc. (the “Company”) to the individual named above (the “Grantee”), pursuant to the ImmunoGen, Inc. Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan (as amended from time to time, the “Plan”). The Company hereby grants, on the date set forth above (the “Grant Date”), the number of restricted stock units listed above (the “Restricted Stock Units”) to the Grantee, giving the Grantee a contingent entitlement to receive, without payment and pursuant to and subject to the terms and conditions set forth in this Agreement and in the Plan, one share of Common Stock (a “Share”) with respect to each Restricted Stock Unit forming part of the Award, subject to adjustment pursuant to paragraph 25 of the Plan in respect of transactions occurring after the date hereof.
IMMUNOGEN, INC. NON-QUALIFIED STOCK OPTION TERMS AND CONDITIONSDirector Option Agreement • March 1st, 2023 • ImmunoGen, Inc. • Pharmaceutical preparations • Massachusetts
This Option Agreement is entered into and made effective as of the grant date referenced in the Grant Detail (the “Date of Grant”) and is between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and the non-employee director of the Company (the “Non-Employee Director”) referenced in the Grant Detail. Certain capitalized terms, to the extent not defined where they first appear in this Option Agreement, are defined in the Company’s Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan (as amended from time to time, the “Plan”).
